Onda 4 Mg/Tab (Ondansetron)

Ondansetron, the active ingredient in Onda 4 Mg/Tab, is a 5-HT3 receptor antagonist presented as a 4 mg tablet for oral use. It helps prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery in adults and children. GNH USA supplies Onda 4 Mg/Tab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Onda 4 Mg/Tab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron is employed across several clinical pathways that involve nausea and vomiting control.

- Chemotherapy‑induced nausea and vomiting (CINV): Reduces the frequency and severity of nausea and vomiting in patients receiving cytotoxic chemotherapy. - Radiation‑induced nausea and vomiting (RINV): Helps control the vomiting that can follow therapeutic radiation. - Post‑operative nausea and vomiting (PONV): Decreases the incidence of nausea and vomiting after surgical procedures. - Hyper‑emesis gravidarum (severe pregnancy‑related nausea): Provides symptomatic relief when other treatments are insufficient.

Side effects are reported with varying frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: general tiredness. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperreflexia, tremor when combined with serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or transient visual disturbances.

When using Onda 4 Mg/Tab, consider the following safety measures.

- Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be observed. - Concomitant serotonergic drugs: avoid or use with caution due to serotonin syndrome risk. - Hepatic impairment: dose adjustment may be required in severe liver disease. - Pregnancy: use only if the potential benefit outweighs risk; discuss with a healthcare professional. - Breastfeeding: monitor infant for possible effects; decision should be clinician‑guided. - Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Ondansetron may interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Apomorphine: concurrent use can cause profound hypotension and loss of consciousness. - Certain anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., codeine, tramadol): ondansetron can affect their metabolism. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): monitor for signs of serotonin syndrome. - Diuretics causing electrolyte loss: correct electrolytes to reduce cardiac risk.